High prevalence of HF, as assessed by NT-proBNP, has been documented in previous studies, implying that the need for guideline-directed medical therapies to prevent HF hospitalization and mortality may be needed by a much greater number of people with T2DM as compared to those who are currently getting it [9,10]. The gene discussed is NPPB; the disease is type 2 diabetes mellitus.